Thomas D Harris
Affiliation: Bristol-Myers Squibb
- Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agentsThomas D Harris
Discovery Research, Bristol Myers Squibb Medical Imaging, 331 Treble Cove Road, N Billerica, Massachusetts 01862, USA
Bioconjug Chem 17:1294-313. 2006..A scintigraphic imaging study with (111)In-TA138 showed a clear delineation of the tumors and rapid clearance of activity from nontarget tissues...
- Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapyThomas D Harris
Discovery Research, Bristol Myers Squibb Medical Imaging, North Billerica, MA 01862, USA
Cancer Biother Radiopharm 18:627-41. 2003..Tumors are visible as early as 0.5 hours PI. Radiotherapy studies in the c-neu Oncomouse model demonstrated a slowing of tumor growth at a dose of 15 mCi/m(2), and a regression of tumors at a dose of 90 mCi/m(2)...
- Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agentsThomas D Harris
Discovery Research, Bristol Myers Squibb Medical Imaging, North, Billerica, Massachusetts 01862, USA
Bioconjug Chem 18:1266-79. 2007..A comparison of therapeutic indices for 90Y-TA138 and 177Lu-15 indicate an improved therapeutic index for the divalent agent. The implications for radiotherapeutic applications and the mechanism of this multivalent effect are discussed...
- 90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalentDavid C Onthank
Discovery R and D, Bristol Myers Squibb Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, USA
Bioconjug Chem 15:235-41. 2004..Therefore, (111)In-TA138 is useful as an imaging surrogate for (90)Y-TA138 and should be able to predict the radiation dosimetry of (90)Y-TA138, a therapeutic radiopharmaceutical for treatment of rapidly growing tumors...
- Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory fociMatthias Broekema
Bristol Myers Squibb Medical Imaging, North Billerica, Massachusetts 01862, USA
J Med Chem 48:6442-53. 2005..The best scintigraphic images were obtained with monovalent HYNIC conjugate 15 using tricine and isonicotinic acid as coligands with HYNIC for coordination with (99m)Tc...
- Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonistShuang Liu
Bristol Myers Squibb Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, USA
Bioconjug Chem 14:1030-7. 2003..The anaerobic formulation described in this study is particularly useful for (90)Y- and (177)Lu-labeling of DOTA-conjugated small biomolecules, which are sensitive to the radiolytic degradation during radiolabeling...
- Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarctionDavid F Meoli
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8017, USA
J Clin Invest 113:1684-91. 2004..This approach may also have significant clinical utility for noninvasively tracking therapeutic myocardial angiogenesis...
- Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivoMehran M Sadeghi
Raymond and Beverly Sackler Cardiovascular Molecular Imaging Laboratory, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Conn, USA
Circulation 110:84-90. 2004..We hypothesized that vascular cell proliferation, a hallmark of injury-induced remodeling, can be tracked by targeting alpha(v)beta3 integrin expression in vivo...
- Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosisPatrick M Winter
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Arterioscler Thromb Vasc Biol 26:2103-9. 2006..Alpha(v)beta3 integrin-targeted paramagnetic nanoparticles were prepared for noninvasive assessment of angiogenesis in early atherosclerosis, for site-specific delivery of antiangiogenic drug, and for quantitative follow-up of response...
- MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticlesTillmann Cyrus
Division of Cardiology, Washington University School of Medicine, Saint Louis, Missouri 63110, USA
J Cardiovasc Magn Reson 8:535-41. 2006..In conclusion, MR molecular imaging with alphavbeta3-integrin or collagen Ill-targeted nanoparticles enables the non-invasive, three-dimensional characterization of arterial pathology unanticipated from routine angiography...
- Imaging of infection and inflammation with an improved 99mTc-labeled LTB4 antagonistJulliette E M van Eerd
Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
J Nucl Med 46:1546-51. 2005..In this study, 2 new hydrazinonicotinamide (HYNIC)-conjugated compounds that are structurally related to DPC11870 were studied to further improve image quality...
- Alphavbeta3-targeted detection of arteriopathy in transplanted human coronary arteries: an autoradiographic studyJiasheng Zhang
Raymond and Beverly Sackler Cardiovascular Molecular Imaging Laboratory, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
FASEB J 19:1857-9. 2005..In conclusion, alphavbeta3 integrin is transiently up-regulated (and activated) in GA and may be targeted by RP748 for detection of the proliferative process in early GA...
- Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytesJulliette E M van Eerd
Department of Nuclear Medicine, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
J Nucl Med 46:786-93. 2005....
- Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticlesAnne H Schmieder
Department of Biomedical Engineering, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
Magn Reson Med 53:621-7. 2005..This technique may be employed to noninvasively detect very small regions of angiogenesis associated with nascent melanoma tumors, and to phenotype and stage early melanoma in a clinical setting...
- Scintigraphic detection of pulmonary aspergillosis in rabbits with a radiolabeled leukotriene b4 antagonistJulliette E M van Eerd
Department of Nuclear Medicine, University Medical Centre Nijmegen, The Netherlands
J Nucl Med 45:1747-53. 2004..The imaging characteristics of 111In-DPC11870 were compared with those of 67Ga-citrate, a radiopharmaceutical commonly used to detect pulmonary infections in patients...
- Imaging of experimental colitis with a radiolabeled leukotriene B4 antagonistJulliette E M van Eerd
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
J Nucl Med 45:89-93. 2004..Imaging characteristics of the (111)In-labeled LTB(4) antagonist (DPC11870) were compared with those of (18)F-FDG and (99m)Tc-HMPAO-granulocytes in a rabbit model of experimental colitis...
- Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imagingPatrick M Winter
Cardiovascular Magnetic Resonance Laboratories, Department of Medicine, Cardiovascular Division, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, Missouri 63110, USA
Cancer Res 63:5838-43. 2003....
- A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious fociJulliette E M van Eerd
Department of Nuclear Medicine, University Medical Centre Nijmegen, Nijmegen, The Netherlands
J Nucl Med 44:1087-91. 2003..In this study, we investigated the in vivo and in vitro characteristics of a new hydrophilic (111)In-labeled LTB(4) antagonist...
- Assessment of myocardial inflammation produced by experimental coronary occlusion and reperfusion with 99mTc-RP517, a new leukotriene B4 receptor antagonist that preferentially labels neutrophils in vivoLaurent M Riou
University of Virginia Health System, Charlottesville, VA 22908 0500, USA
Circulation 106:592-8. 2002....